EVAX (Evaxion Biotech AS) Total Stockholders Equity : $-1.65 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Total Stockholders Equity?

Evaxion Biotech AS's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-1.65 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Evaxion Biotech AS's Book Value per Share for the quarter that ended in Dec. 2024 was $-1.18. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Evaxion Biotech AS's Debt-to-Equity for the quarter that ended in Dec. 2024 was -6.11.

Evaxion Biotech AS Total Stockholders Equity Historical Data

The historical data trend for Evaxion Biotech AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Total Stockholders Equity Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

7.04

32.44

8.30

-4.73

-1.65

Evaxion Biotech AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															-4.73	5.53	1.25	0.07	-1.65

Evaxion Biotech AS (NAS:EVAX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Evaxion Biotech AS's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-1.652	-	0)	/	1.403
	=	-1.18

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Evaxion Biotech AS's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.473	+	9.628)	/	-1.652
	=	-6.11

Evaxion Biotech AS Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.